BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Press Releases

  Seeing is Believing: New Probes Reveal Proteins Inside Living Cells with Unprecedented Clarity

  April 22, 2026

   · 

  5 min read
• Press Releases

  Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance

  April 22, 2026

   · 

  27 min read
• Press Releases

  AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder

  April 22, 2026

   · 

  12 min read
• Press Releases

  Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth

  April 22, 2026

   · 

  1 min read
• Press Releases

  Oncology Ventures Announces Oversubscribed $62 Million Fund II to Accelerate the Future of Cancer Care

  April 22, 2026

   · 

  3 min read
• Press Releases

  Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader

  April 22, 2026

   · 

  4 min read
• Press Releases

  BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6

  April 22, 2026

   · 

  2 min read
• 

  GLP-1

  Lilly, Novo dip as proposed Medicare coverage for GLP-1 pilot thrown off balance

  Two of the biggest insurance providers have expressed reluctance to participate in the government’s BALANCE program that would have made GLP-1 drugs more affordable to patients.

  April 22, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Approvals

  Merck steps up as ‘meaningful competitor’ to Gilead with HIV pill approval

  The newly approved HIV drug Idvynso will also help Merck diversify as loss of exclusivity looms over its top-selling product, the mega-blockbuster cancer drug Keytruda.

  April 22, 2026

   · 

  1 min read

   · 

  Tristan Manalac
• 

  Regulatory

  Amid US ordeal, Moderna wins EU approval for flu/COVID-19 combo shot

  In the U.S., Moderna withdrew its approval application for the combination vaccine in May last year and the timeline for resubmission remains uncertain.

  April 22, 2026

   · 

  2 min read

   · 

  Tristan Manalac